ZacksJun 25, 2026, 12:00 AMnasdaq
Gilead's Breast Cancer Drug Trodelvy Wins FDA Nod for Expanded Use
GILD wins FDA approval to expand Trodelvy into first-line metastatic triple-negative breast cancer, opening a broader treatment opportunity.
Open articleRTTNewsJun 25, 2026, 12:00 AMnasdaq
Gilead's Trodelvy Gets FDA Nod For First-Line Treatment Of Metastatic Triple-Negative Breast Cancer
(RTTNews) - Gilead Sciences, Inc. (GILD) announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvy for first-line treatment of metastatic triple-negative breast cancer (mTNBC).
Open articleThe Motley FoolJun 25, 2026, 12:00 AMnasdaq
This ETF Has More Than Doubled the S&P 500's Returns Over the Past Decade. Is It a Buy for the Next Decade?
Key PointsThe "Magnificent Seven" stocks account for more than a third of the Invesco QQQ Trust ETF (QQQ).
Open articleRTTNewsJun 25, 2026, 12:00 AMnasdaq
Gilead's Trodelvy Wins FDA Approval For First-Line Metastatic Triple-Negative Breast Cancer
(RTTNews) - Gilead Sciences Inc. (GILD) said Thursday that the U.S. Food and Drug Administration has approved Trodelvy for the first-line treatment of adults with unresectable locally advanced or metastatic Triple-Negative Breast Cancer.
Open articleZacksJun 24, 2026, 12:00 AMnasdaq
Gilead Wins EC Approval to Expand Trodelvy's Label in Metastatic TNBC
Gilead secures EC approval to expand Trodelvy into first-line metastatic TNBC, marking a new treatment option and broadening its oncology reach.
Open articleRTTNewsJun 23, 2026, 12:00 AMnasdaq
European Commission Grants Marketing Rights For Gilead's Trodelvy In Treating Breast Cancer
(RTTNews) - Gilead Sciences, Inc. (GILD) announced the receipt of marketing approval from the European Commission for Trodelvy in treating unresectable or metastatic Triple-negative Breast Cancer.
The approval was based on data from the Phase 3 ASCENT-03 trial, which demonstrat
Open articleMarketBeatJun 23, 2026, 12:00 AMnasdaq
The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch.
The biotech sector has spent close to a year in no man's land. While technology, AI, and the broader market raced to new highs, biotechs have largely sat out the rally. But that may finally be changing. The sector is now setting up for what could be one of the most compelling mu
Open articleRTTNewsJun 23, 2026, 12:00 AMnasdaq
Gilead Sciences Secures European Commission Marketing Authorization For Trodelvy
(RTTNews) - Tuesday, Gilead Sciences, Inc. (GILD) announced that the European Commission has granted marketing authorization for Trodelvy, also known as sacituzumab govitecan-hziy, as monotherapy for the treatment of adult patients with unresectable or metastatic triple-negative
Open articleZacksJun 17, 2026, 12:00 AMnasdaq
The Zacks Analyst Blog Highlights Gilead Sciences, Merck and GSK
Gilead Sciences won FDA acceptance for a filing that could expand Yeztugo into a once-weekly oral HIV prevention option, broadening its HIV portfolio.
Open articleZacksJun 16, 2026, 12:00 AMnasdaq
FDA Accepts Gilead's Filing for Weekly Oral Yeztugo for HIV Prevention
Gilead seeks FDA approval for once-weekly oral Yeztugo for HIV prevention, aiming to expand access with a new long-acting PrEP option.
Open articleRTTNewsJun 16, 2026, 12:00 AMnasdaq
FDA Accepts Gilead's SNDA For Once-Weekly Oral Yeztugo In HIV PrEP; PDUFA Set For February 2027
(RTTNews) - Gilead Sciences, Inc. (GILD) announced that the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) for Yeztugo (lenacapavir) for the prevention of HIV as pre-exposure prophylaxis (PrEP) and has set a Prescription Drug User Fe
Open articleBNK InvestJun 12, 2026, 12:00 AMnasdaq
XLV, AMGN, TMO, GILD: ETF Inflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $415.7 million dollar inflow -- that's a 1.1% increase week o
Open article